SCHEMBL20111646

SCHEMBL20111646

C=CCCc1ccc(-c2ccc3c(c2F)-c2c-3cc(OCC)c(F)c2F)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.37
GABRB2 P47870 3/20 0.37
FFAR4 Q5NUL3 2/20 0.35
LMNA P02545 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32
MEN1 O00255 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KMT2A Q03164 2/20 0.31
CYP2D6 P10635 1/20 0.31
CNR2 P34972 1/20 0.31
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
MPL P40238 1/20 0.30
KDM4E B2RXH2 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17123330 0.85 GABRA1 (0.41) GABRA1GABRB2FFAR4LMNAFGFR1
SCHEMBL22277557 0.83 GABRA1 (0.39) GABRA1GABRB2FFAR4LMNAFGFR1
SCHEMBL22277605 0.83 GABRA1 (0.39) GABRA1GABRB2FFAR4LMNAFGFR1
SCHEMBL20102495 0.83 MPL (0.30) MPL
SCHEMBL20111644 0.80 MEN1 (0.33) GABRA1GABRB2MEN1ALDH1A1KMT2A
SCHEMBL13754791 0.80 GABRA1 (0.37) GABRA1GABRB2FFAR4LMNAFGFR1
SCHEMBL12834608 0.79 GABRA1 (0.37) GABRA1GABRB2FFAR4LMNAS1PR1
SCHEMBL20803683 0.77 GABRA1 (0.40) GABRA1GABRB2FFAR4LMNAS1PR1
SCHEMBL13235510 0.77 GABRA1 (0.37) GABRA1GABRB2FFAR4LMNAFGFR1
SCHEMBL22011102 0.77 GABRA1 (0.35) GABRA1GABRB2FFAR4LMNAS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2019-06-18 US disclosed
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE YBX1, PIEZO1, C1S GABRA1 2640/4885GABRB2 3408/4885FFAR4 309/4885
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device YBX1, PIEZO1, C1S GABRA1 2640/4885GABRB2 3408/4885FFAR4 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.